Just Us

I’d like to believe I leave this place a little less lonely, a little more just. - me. Immunology investor when I’m not fighting fascists.

[Just Us @Nightroads]

Still relevant, still fighting...
All You Fascists
Written by Woody Guthrie c. 1942
Sung by Billy Bragg and Wilco
https://t.co/tzFHC6iHIF

[Andrew @amac0668]

@matthewjdowd Well said Matthew. If you're quoting Hitler in your newsletter, you are indeed a hate group.

[Just Us @Nightroads]

@rigatoni33 @rigatoni33 …from iHub a dozen years ago? Good to see you. In fact, saw a post back pre-BHVN on your board about PRTG. Did some DD, liked the management. Bought in for that ride. In this one now. Eyes on SITC in November.

[Just Us @Nightroads]

“A majority” $PRTG @PortageBiotech

[Just Us @Nightroads]

$PRTG @PortageBiotech some very good news coming out today at #ASCO2023. #iNkt “Several target lesions were substantially reduced in size or completely resolved, and a majority of target lesions being clinically stable after twelve weeks,” said Dr. Ian Walters.

[Just Us @Nightroads]

$PRTG @PortageBiotech some very good news coming out today at #ASCO2023. #iNkt “Several target lesions were substantially reduced in size or completely resolved, and a majority of target lesions being clinically stable after twelve weeks,” said Dr. Ian Walters.

[Portage Biotech @PortageBiotech]

We’re pleased to share updated interim data on our lead #iNKT engager in a Phase 1/2 study for the treatment of #melanoma and #NSCLC at #ASCO23. For more details on the poster, click here: https://t.co/urrMMYy3zB

[Just Us @Nightroads]

@CultrHack This made my Saturday late night scrolling…where is Art Leboe? #LSUG

[Just Us @Nightroads]

$PRTG. @PortageBiotech We’ve been waiting a very long time for good news. The abstract certainly points to that. And while there were 2 CR, 1 PR, it’s the 10 SD. Is that something we’re gonna like? A lot? Hey Ian, would you host a q and a for investors after #ASCO?

[JP @jamvest20]

$PRTG Ian walters CEO of portage is on this panel to discuss the next innovations in medicine and primarily the future of immuno-oncology (inkt )
right after there asco poster release on the 3rd June 😉
#ASCO23

[Just Us @Nightroads]

$PRTG

[JP @jamvest20]

@JacobPlieth $PRTG early stage in p1/p2 ,wont necessary see the press others receive,their abstract is worth a look
Strong early efficacy results at low/mid dose in their inkt agonist treating nsclc stage 4.
Patients had not repsonded to previous therapies and PD-1.
https://t.co/evsN8KbsVA

[Just Us @Nightroads]

$PRTG @PortageBiotech

[JP @jamvest20]

$PRTG huge PR coming in the next week or so on early efficacy seen in their lead #inkt asset imm60.
NSCLC
100% patients prior pd-1
No grade 3-5
19 lesions (2CR /10 SD /1 MR /6 PR
All at low/ mid dose range
Results be it early are up there with KEYTRUDA! $21bn pa drug!
#ASCO23

[Just Us @Nightroads]

@PortageBiotech @molecule2markt Where’s the PR on the ASCO Poster?

[Just Us @Nightroads]

$PRTG

[JP @jamvest20]

To note stable disease(SD) in 10no lesion given this is stage 4 nsclc patients is equally as credible at their low dose (1-3mg) imm60 could be a tangible alternative to both chemo and or PEM . 12month progression free survival will be very telling $PRTG

[Just Us @Nightroads]

@jamvest20 Very good response. Early. But good.

[Just Us @Nightroads]

$PRTG. It’s a big deal!!

[GMF78 @GMF782]

$PRTG “well tolerated” “no MTD was determined” “2 lesions completely resolved” we can’t forget these patients have sadly been through several other treatments that failed. Well done @PortageBiotech you seem to be improving outcomes with PORT2 🙏 #ASCO23 #CancerResearch

[Just Us @Nightroads]

$PRTG. We’ve waited a few years for confirmation. I like what I am reading.

[JP @jamvest20]

$prtg CR in target lesions without establishing MTD.

Patients have failed all other treatments so quite incredible early results seen

#ASCO23

[Elmo @elmo]

Elmo had so much fun with the Haim sisters! @HAIMtheband, let Elmo know if you need a new member. "Elmo Haim" sounds pretty good to Elmo! Ha ha ha! ❤️

[Aphex @Windowlicker79]

Take a listen and realise the potential of $PRTG. At this price it's the bargain of the century. ASCO is weeks away where the data will prove the investment.

[Just Us @Nightroads]

$PRTG. Years, now just 4 weeks!

[Aphex @Windowlicker79]

$PRTG are excited to be presenting an update on our study of PORT-2 (#iNKT engager) for the treatment of #NSCLC & #melanoma at @ASCO, us investors have waited years for this data, time is now!

[Governor Gavin Newsom @CAgovernor]

CA is poised to be the 4th largest economy in the world, has the highest GDP of any state, & the most small businesses in the U.S.

At the @MilkenInstitute Global Conference, Governor @GavinNewsom highlighted CA's commitment to expanding freedom & economic opportunity for all.

[Just Us @Nightroads]

$PRTG This is it! I know a number of investors have been waiting to see this. Coincides with the ASCO conference poster. We get solid update on IMM60 alone and in combo with Keytruda, I’ll be a very happy investor.

[JP @jamvest20]

$PRTG
Boom!
Global trial site updated with June 5th start.
This is running in parallel with the going p1/p2 uk arm of the trial.
Data is coming ! And quick with 12 new trial locations in the US and spain.
Merck collab is really kicking into action now $MRK

[Just Us @Nightroads]

$PRTG

[JP @jamvest20]

$PRTG to remind people who may not be familiar with how stacked this pipeline is with both blockbuster assets fully owned!

Inkt PORT2&3(100% owned)
adenosine PORT6&7 (100% owned)
INT230-6 PORT 1 (8% owned)
SAUG 1 -PORT 4 (70% owned)
STing VLP - 5 (44% owned)

[Just Us @Nightroads]

$PRTG Investors are at the start of data rolling in. ASCO in a June we get data on Port-2 alone and in combination with Keytruda. The cohort is small, larger trial starts June, more data at SITC in Nov. And funny, the trial was designed by Merck. This year could see a breakout.

[JP @jamvest20]

$PRTG
Unlike other biotechs portage have designed import-201 trial to meet the exact clinical requirements $BMS & $MRK require. It helps when the chairman worked at BMS / brought nivolumab to market!

https://t.co/oP7ipweTiZ